NASDAQ:CGON CG Oncology Q3 2025 Earnings Results & Report $71.31 +1.16 (+1.65%) As of 12:11 PM Eastern This is a fair market value price provided by Massive. Learn more. CG Oncology met analyst earnings expectations and beat on revenue in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$0.57 versus the -$0.57 consensus estimate, while revenue of $158 thousand topped the $73 thousand estimate by $85 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 14, 2025TimeBefore Market OpensConference Call8:00 AM ET CG Oncology EPS ResultsActual EPS-$0.57Consensus EPS -$0.57Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersCG Oncology Revenue ResultsActual Revenue$158 thousandExpected Revenue$73 thousandBeat/MissBeat by +$85.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) CG Oncology Q3 2025 Earnings FAQ Did CG Oncology beat earnings estimates for Q3 2025? CG Oncology (NASDAQ:CGON) reported earnings of -$0.57 per share for Q3 2025, matching the consensus estimate of -$0.57. The report was announced on Friday, November 14, 2025. What was CG Oncology's revenue for Q3 2025? CG Oncology reported revenue of $158 thousand for Q3 2025, against a consensus estimate of $73 thousand. CG Oncology Earnings HeadlinesCG Oncology FY2026 Earnings Forecast Lifted by HC WainwrightNovember 12 at 2:15 AM | americanbankingnews.comCG Oncology (NASDAQ:CGON) Stock Price Target Cut by GuggenheimNovember 11 at 2:51 AM | americanbankingnews.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 13 at 1:00 AM | Behind the Markets (Ad)What CG Oncology (CGON)'s Third Quarter Earnings Means For ShareholdersNovember 10 at 3:37 PM | finance.yahoo.comCG Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 6, 2026 | marketscreener.comMCG Oncology Gains on Q3 ResultsNovember 6, 2026 | baystreet.caSee More CG Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CG Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CG Oncology and other key companies, straight to your email. Email Address About CG OncologyCG Oncology (NASDAQ:CGON) is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response. CG Oncology has no approved commercial products. Its clinical development program includes studies of cretostimogene alone and in combination with other cancer treatments. The company is led by President and Chief Executive Officer Arthur Kuan.View CG Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
